Universal Beteiligungs und Servicegesellschaft mbH Sells 396,232 Shares of TransMedics Group, Inc. $TMDX

Universal Beteiligungs und Servicegesellschaft mbH trimmed its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 85.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 65,345 shares of the company’s stock after selling 396,232 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.19% of TransMedics Group worth $7,332,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in TMDX. Royal Bank of Canada boosted its holdings in shares of TransMedics Group by 47.9% during the 1st quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock valued at $1,788,000 after buying an additional 8,604 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in TransMedics Group by 4.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock valued at $1,314,000 after acquiring an additional 868 shares during the period. Goldman Sachs Group Inc. boosted its stake in TransMedics Group by 20.6% during the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after acquiring an additional 86,721 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in TransMedics Group in the second quarter worth about $224,000. Finally, Park Avenue Securities LLC purchased a new stake in TransMedics Group in the second quarter worth about $445,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Stock Down 2.0%

TransMedics Group stock opened at $135.30 on Monday. TransMedics Group, Inc. has a 12 month low of $59.24 and a 12 month high of $156.00. The stock has a fifty day simple moving average of $132.83 and a two-hundred day simple moving average of $122.96. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43. The firm has a market cap of $4.62 billion, a price-to-earnings ratio of 54.78 and a beta of 2.03.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.37 by $0.29. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The company had revenue of $143.82 million for the quarter, compared to analysts’ expectations of $145.33 million. During the same period last year, the firm posted $0.12 earnings per share. TransMedics Group’s revenue was up 32.2% compared to the same quarter last year. Equities analysts predict that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Activity at TransMedics Group

In other news, Director Edward M. Basile sold 4,142 shares of TransMedics Group stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total value of $540,323.90. Following the completion of the sale, the director directly owned 2,866 shares in the company, valued at $373,869.70. The trade was a 59.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Anil P. Ranganath sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total transaction of $435,660.00. Following the transaction, the insider directly owned 13,955 shares of the company’s stock, valued at $2,026,545.10. The trade was a 17.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 13,062 shares of company stock worth $1,797,634. 7.00% of the stock is owned by insiders.

Analysts Set New Price Targets

TMDX has been the subject of several recent research reports. Jefferies Financial Group assumed coverage on TransMedics Group in a research report on Monday, October 13th. They issued a “buy” rating and a $145.00 price target on the stock. Wall Street Zen upgraded TransMedics Group from a “hold” rating to a “buy” rating in a research note on Sunday, December 28th. Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a research note on Wednesday, October 8th. Canaccord Genuity Group lifted their price target on TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Finally, Zacks Research cut shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 6th. Six research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $144.25.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.